News
Identifying the priorities that translate to strong business outcomes—and separating the top performers from the average ...
Merck Animal Health will invest $895 million to expand vaccine manufacturing and R&D in Kansas, while Lilly is committing ...
Proposed cuts to Medicaid will have significant impacts on the health industry. One area that will be heavily impacted by ...
On Sunday, President Trump posted to Truth Social that he planned on implementing a most-favored-nation policy for ...
The Avmapki Fakzynja Co-Pack marks the first FDA-approved treatment for adult patients with KRAS-mutated recurrent low-grade ...
Beyond technology, regulations weigh heavily on the minds of pharma executives. Four out of 10 leaders believe regulatory ...
Under terms of the deal, Alchemab will lead early Phase I trials for ATLX-1282 in amyotrophic lateral sclerosis, while Lilly ...
Will Pih, co-founder, Two Labs, explains how ongoing regulatory uncertainty is slowing clinical trial activity and hiring ...
Lilly announced several changes to its executive leadership team. 1 These changes are mostly related to the company’s ...
Chip Parkinson, CEO, GiftHealth, explains how AI-powered data integration is bringing new hope to patients by revealing ...
Gilead’s Livdelzi Shows Lasting Efficacy in Primary Biliary Cholangitis, Regardless of Prior Therapy
Interim results from the ongoing Phase III ASSURE trial demonstrated that Livdelzi maintained a consistent biochemical ...
The use of RWD data in place of placebo groups is improving various elements across the clinical trial space.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results